• Current Controlled Trials (www.controlled-trials.com)
• International AIDS Society
Restrictions
No date or language restriction will be applied.
INCLUSION CRITERIA

Types of studies
• Randomized and non-randomized trials • Prospective and retrospective cohorts
• Case control studies
• Unsystematic observations (case series or case reports) will be excluded from all analyses
Types of participants
Inclusions:
• Women exposed to CTX during pregnancy
Types of interventions
• CTX during pregnancy. Women exposed to Trimethoprim will also be eligible for inclusion
Types of comparitors
• Pregnant women not exposed to CTX during pregnancy 
Types of outcomes
ASSESSMENT OF METHODOLOGICAL QUALITY
The following data will be extracted as potentially influencing the methodological quality of studies:
• Direct ascertainment of CTX use 
DATA ANALYSIS
Prevalence estimates
Point estimates and 95% confidence intervals (95% CI) will be calculated for the proportion of birth defects reported among live births for each study. Spontaneous and induced abortions and stillbirths will be excluded from the denominator of birth defects, consistent with reporting norms. The variance of the raw proportions will be stabilised using a Freeman-Tukey type arcsine square-root transformation and estimates pooled using a DerSimonian-Laird random effects model. Prevalence and 95%CIs will be calculated for all secondary outcomes. Because the background prevalence rates of these outcomes varies considerably across study settings, these data will not be pooled, but where rates are reported for women exposed to both efavirenz-and non-efavirenz-based regimens, pooled relative risks will be calculated.
Meta-analysis
For case-control studies reporting on birth outcomes of infants exposed to CTX during the first trimester vs. infants not exposed to any drug, odds ratios (ORs) and 95% CIs will be calculated and data pooled using the DerSimonian-Laird random effects method.
In the case of zero outcome events in one arm, the Haldane method will be applied, adding 0.5 to each arm.
Heterogeneity
The τ 2 statistic will be calculated to assess the proportion of overall variation attributable to between-study heterogeneity as this is less affected by the number of studies than the more commonly used I 2 statistic. Subgroup analyses will be conducted to assess the potential effect on the pooled estimates of study design, study location, duration of efavirenz exposure, and status of publication. A p-value less than 0.05 will be considered to be significant.
Statistical software
Analyses will be conducted using Stata (version 12, www.stata.com). 
Protocol
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
4, Protocol
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Protocol
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
4, Protocol
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
5, Protocol
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis.
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Section/topic # Checklist item Reported on page #
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
5, Protocol
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
6
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. 
8, Supplementary tables
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).
6, Figure 2
DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
8-11
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
FUNDING Funding Supplementary Table 1: 1/76** Rash **2 additional cases of rash were reported but these were unrelated to cotrimoxazole use
